125532-13-0

Basic information

• Product Name: 3-Pyridinecarboxylic acid, 6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-, methyl ester
• CAS NO: 125532-13-0
• Molecular Formula: C14H23NO3Si
• Molecular Weight: 281.427
• Mol File: 125532-13-0.mol

Chemical Properties

• CAS DataBase Reference: 3-Pyridinecarboxylic acid, 6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarboxylic acid, 6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-, methyl ester(125532-13-0)
• EPA Substance Registry System: 3-Pyridinecarboxylic acid, 6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-, methyl ester(125532-13-0)

Safety Data

• Hazardous Substances Data: 125532-13-0(Hazardous Substances Data)

Upstream product

• 56026-36-9 methyl 6-(hydroxymethyl)nicotinate 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Relevant articles and documents

A divergent strategy for attaching polypyridyl ligands to peptides

(Figure Presented) A divergent method for incorporating polypyridyl ligands into peptides is reported. Three N-Fmoc unnatural amino acids (1-3) that contain varying linkers between the α-carbon and a 2-(hydroxymethyl) pyridyl group were synthesized in enantioenriched form. These amino acids were used as anchors for incorporating multidentate ligands onto a peptide chain in a site-specific fashion. Multiple peptide-ligand conjugates were synthesized from single precursors by solution- or solid-phase methods. Peptides containing more than one metal-binding unit can be produced by this method.

Triazolopyridazine derivative as well as preparation method, pharmaceutical composition and application thereof

The invention relates to triazolopyridazine derivatives as well as a preparation method, a pharmaceutical composition and application thereof. The invention provides a compound shown in a general formula (I), cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound, and a preparation method of the compound, the cis-trans isomers, the enantiomers, the diastereoisomers, the racemes, the solvates, the hydrates or the pharmaceutically acceptable salts or the prodrugs of the compound; preparation method thereof; pharmaceutical compositions containing the compounds, and the use of the compounds as alpha 5-GABAA receptor modulators, wherein R 1, R 2, and Z are as defined in the specification. pharmaceutical compositions containing the compounds and application of the compounds as alpha-5-GABAA receptor modulators, wherein R1, R2 and Z are as defined in the specification.

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Compounds and Their Use in Treating Cancer

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.

TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A PYRIDINE OR PYRAZINE MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR

Compounds having a structure according to formula (I) where R1 and Ar are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.

MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a cereblon, Von Hippel-Lindau ligase-binding moiety, Inhibitors of Apotosis Proteins, or mouse double-minute homolog 2 ligand, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Design, Preparation, and Characterization of Zn and Cu Metallopeptides Based On Tetradentate Aminopyridine Ligands Showing Enhanced DNA Cleavage Activity

The conjugation of redox-active complexes that can function as chemical nucleases to cationic tetrapeptides is pursued in this work in order to explore the expected synergistic effect between these two elements in DNA oxidative cleavage. Coordination complexes of biologically relevant first row metal ions, such as Zn(II) or Cu(II), containing the tetradentate ligands 1,4-dimethyl-7-(2-pyridylmethyl)-1,4,7-triazacyclononane (Me2PyTACN) and (2S,2S′)-1,1′-bis(pyrid-2-ylmethyl)-2,2′-bipyrrolidine ((S,S′)-BPBP) have been linked to a cationic LKKL tetrapeptide sequence. Solid-phase synthesis of the peptide-tetradentate ligand conjugates has been developed, and the preparation and characterization of the corresponding metallotetrapeptides is described. The DNA cleavage activity of Cu and Zn metallopeptides has been evaluated and compared to their metal binding conjugates as well as to the parent complexes and ligands. Very interestingly, the oxidative Cu metallopeptides 1Cu and 2Cu show an enhanced activity compared to the parent complexes, [Cu(PyTACN)]2+ and [Cu(BPBP)]2+, respectively. Under optimized conditions, 1Cu displays an apparent pseudo first-order rate constant (kobs) of ～0.16 min-1 with a supercoiled DNA half-life time (t1/2) of ～4.3 min. On the other hand, kobs for 2Cu has been found to be ～0.11 min-1 with t1/2 ≈ 6.4 min. Hence, these results point out that the DNA cleavage activities promoted by the metallopeptides 1Cu and 2Cu render ～4-fold and ～23 rate accelerations in comparison with their parent Cu complexes. Additional binding assays and mechanistic studies demonstrate that the enhanced cleavage activities are explained by the presence of the cationic LKKL tetrapeptide sequence, which induces an improved binding affinity to the DNA, thus bringing the metal ion, which is responsible for cleavage, in close proximity.